Sanofi Ventures, Mass General Brigham Ventures, GV and Alexandria Venture Investments have contributed to a $77m round for Rome Therapeutics.
US-based cancer and autoimmune disease drug developer Rome Therapeutics closed a $77m series B round on Tuesday featuring investment subsidiaries of corporates Sanofi, Mass General Brigham, Alphabet and Alexandria Real Estate Equities.
Venture capital fund Section 32 led the round, which also drew in investment from Casdin Capital, Andreessen Horowitz and Arch Venture Partners.
Pharmaceutical firm Sanofi, healthcare provider Mass General Brigham, internet and technology group Alphabet and life sciences real estate investment trust Alexandria Real Estate Equities were represented…
